Published in Am J Transplant on March 13, 2015
Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. J Am Soc Nephrol (2016) 0.79
The Banff 2015 Kidney meeting report: Current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant (2016) 0.78
Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation. Front Immunol (2016) 0.78
ABO-compatible liver allograft antibody-mediated rejection: an update. Curr Opin Organ Transplant (2015) 0.78
Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant? PLoS One (2016) 0.78
Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation. World J Gastroenterol (2015) 0.76
Renal Transplant Patients Biopsied for Cause and Tested for C4d, DSA, and IgG Subclasses and C1q: Which Humoral Markers Improve Diagnosis and Outcomes? J Immunol Res (2017) 0.76
Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R. Hepatology (2016) 0.76
Clinically relevant interpretation of solid phase assays for HLA antibody. Curr Opin Organ Transplant (2016) 0.76
The Role of Humoral Alloreactivity in Liver Transplantation: Lessons Learned and New Perspectives. J Immunol Res (2017) 0.75
From Humoral Theory to Performant Risk Stratification in Kidney Transplantation. J Immunol Res (2017) 0.75
Unraveling the Role of Allo-Antibodies and Transplant Injury. Front Immunol (2016) 0.75
Donor-specific HLA-antibodies: the difficulty of separating the wheat from the chaff. Am J Transplant (2015) 0.75
High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med (1973) 9.90
Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test. Transplantation (1968) 8.51
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol (1978) 6.88
Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50
Autologous stimulation of human lymphocyte subpopulation. J Exp Med (1975) 4.80
Cytotoxins in disease. Autocytotoxins in lupus. N Engl J Med (1970) 4.40
Serotyping for homotransplantation. X. Survival of 196 grafted kidneys subsequent to typing. Transplantation (1967) 4.16
Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05
Kidney preservation for transportation. Initial perfusion and 30 hours' ice storage. Lancet (1969) 3.67
Effect of blood transfusions on subsequent kidney transplants. Transplant Proc (1973) 3.42
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Nomenclature for factors of the HLA system, 2010. Tissue Antigens (2010) 3.22
Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med (1995) 3.11
Chronic survival after human renal homotransplantation. Lymphocyte-antigen matching, pathology and influence of thymectomy. Ann Surg (1965) 3.00
Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet (1981) 2.92
Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med (1978) 2.52
Transplantation of kidneys from donors whose hearts have stopped beating. N Engl J Med (1998) 2.48
Immunosuppression, generic drugs and the FDA. Am J Transplant (2011) 2.43
Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med (1990) 2.40
Thoracic duct drainage before and after cadaveric kidney transplantation. Surg Gynecol Obstet (1979) 2.33
Heterologous antilymphocyte glubulin, histoincompatiblity matching, and human renal homotransplantation. Surg Gynecol Obstet (1968) 2.23
The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation (1995) 2.13
Equitable allocation of HLA-compatible kidneys for local pools and minorities. N Engl J Med (1994) 2.12
Reactivity of lymphocytes from normal persons on cultured tumor cells. Cancer Res (1973) 2.11
Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry. N Engl J Med (1992) 2.09
Human renal transplants. I. Glomerular changes. Lab Invest (1967) 2.06
Characterization of sialosylated Lewisx as a new tumor-associated antigen. Cancer Res (1984) 2.02
Shipment of human islets for transplantation. Am J Transplant (2007) 2.01
American Society of Transplant Surgeons transplant center outcomes requirements--a threat to innovation. Am J Transplant (2009) 2.00
Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94
Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology (1993) 1.90
Nomenclature for factors of the HLA system, 2002. Tissue Antigens (2002) 1.89
Analysis of HL-A incompatibility in human renal transplants. Tissue Antigens (1971) 1.89
A semimicro mixed leukocyte culture test. Transplantation (1971) 1.85
Total hepatectomy and liver replacement (orthotopic liver transplantation) for primary hepatic malignancy. World J Surg (1982) 1.84
Juvenile myoclonic epilepsy (JME) may be linked to the BF and HLA loci on human chromosome 6. Am J Med Genet (1988) 1.82
End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation (2001) 1.79
Serotyping for homotransplantation. V. Evaluation of a matching scheme. Transplantation (1966) 1.78
Enhancement of human kidney allografts by cold B-lymphocyte cytotoxins. Lancet (1978) 1.70
Spinocerebellar ataxia and HLA linkage: risk prediction by HLA typing. N Engl J Med (1977) 1.67
Multiple sclerosis: association with HL-A3. Tissue Antigens (1972) 1.65
Successful renal allografts across a positive cross-match for donor B-lymphocyte alloantigens. Lancet (1976) 1.63
Disturbance of HL-A antigen frequency in Psoriasis. N Engl J Med (1972) 1.63
Cross reactions between human transplantation antigens and bacterial lipopolysaccharides. Transplantation (1973) 1.60
Thoracic duct fistula and renal transplantation. Ann Surg (1979) 1.60
Influence of race on kidney transplant survival. Transplant Proc (1977) 1.58
Increased prevalence of W27 in juvenile rheumatoid arthritis. N Engl J Med (1974) 1.58
Treatment of lymphopenic hypogammaglobulinemia and bone-marrow aplasia by transplantation of allogeneic marrow. Crucial role of histocompatiility matching. N Engl J Med (1969) 1.58
Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion (2000) 1.58
Impact of pretransplant renal function on survival after liver transplantation. Transplantation (1995) 1.58
Nomenclature for factors of the HLA system, 2004. Tissue Antigens (2005) 1.57
Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant (2011) 1.56
HLA matching and cadaver kidney transplant survival in North America: influence of center variation and presensitization. Transplantation (1977) 1.56
Empirical validation of the Essen-Möller probability of paternity. Am J Hum Genet (1986) 1.56
Follow-up study of juvenile chronic polyarthritis with particular reference to histocompatibility antigen W. 27. Ann Rheum Dis (1974) 1.55
Readmission to the intensive care unit after liver transplantation. Crit Care Med (2001) 1.54
Anti-HLA antibodies after solid organ transplantation. Transplantation (2000) 1.54
Metallic stents for the treatment of intrahepatic biliary strictures after liver transplantation. J Vasc Interv Radiol (1996) 1.51
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant (2014) 1.50
HL-A antigens and antibody response after influenza A vaccination. Decreased response associated with HL-A type W16. N Engl J Med (1976) 1.49
HLA and the inheritance of multiple sclerosis: linkage analysis of 72 pedigrees. Am J Hum Genet (1980) 1.46
Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology (1998) 1.46
Cytotoxins in disease. 3. Antibodies against lymphocytes produced by vaccination. Transplantation (1970) 1.46
HLA genotypic study of insulin-dependent diabetes the excess of DR3/DR4 heterozygotes allows rejection of the recessive hypothesis. Diabetes (1983) 1.45
Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant (2013) 1.44
Suppression of lymphocyte transformation by aspirin. Lancet (1973) 1.43
Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant (2007) 1.43
Twins with two different fathers identified by HLA. N Engl J Med (1978) 1.43
Paired kidney exchange is not a solution to ABO incompatibility. Transplantation (1998) 1.43
De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact. Liver Transpl Surg (1998) 1.42
LIGHT AND ELECTRON MICROSCOPIC STUDY OF BIOPSIES FROM THIRTY-THREE HUMAN RENAL ALLOGRAFTS AND AN ISOGRAFT 134-212 YEARS AFTER TRANSPLANTATION. Ann N Y Acad Sci (1996) 1.42
The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors. Transplantation (1992) 1.41
HL-A W27--a clue to the diagnosis and pathogenesis of Reiter's syndrome. N Engl J Med (1974) 1.41
Effect of pentoxifylline on hepatic ischemia and reperfusion injury. Surgery (1997) 1.41
Poor kidney-transplant survival in recipients with frozen-blood transfusions or no transfusions. Lancet (1974) 1.40
HLA matching assessed from early graft function. Transplant Proc (1987) 1.40
Nomenclature for factors of the HLA system, 1998. Tissue Antigens (1999) 1.40
Genetics of four new HL-A specificities in the Caucasian and Negro populations. Transplant Proc (1971) 1.38
Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation (1981) 1.38
Serotyping for homotransplantation. XIX. Experience with an interhospital scheme of cadaver-kidney sharing and tissue typing. JAMA (1969) 1.38
Analyses of the UNOS Scientific Renal Transplant Registry at three years--early events affecting transplant success. Transplantation (1992) 1.37
HLA-B14 antigen and postencephalitic Parkinson's disease. Their association in an American-Jewish ethnic group. Arch Neurol (1980) 1.37
The influence of preservation injury on rejection in the hepatic transplant recipient. Transplantation (1990) 1.37
Group-specific human granulocyte antigens on a chronic myelogenous leukemia cell line with a Philadelphia chromosome marker. Blood (1977) 1.35
Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol (1999) 1.34
Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther (1995) 1.33
Cross-reactions between streptococcal M proteins and human transplantation antigens. Science (1970) 1.33
Presensitization and kidney transplant failures. Postgrad Med J (1971) 1.33
A new microcellular cytotoxicity test based on calcein AM release. Hum Immunol (1993) 1.32
Serotyping for homotransplantation. IX. Evaluation of leukocyte antigen matching with the clinical course and rejection types. Transplantation (1967) 1.32
Sjögren's syndrome association with HLA-Dw3. N Engl J Med (1977) 1.32
Serotyping for homotransplantation. XVI. Analysis of kidney transplants from unrelated donors. N Engl J Med (1968) 1.31
Close genetic linkage between diabetes mellitus and kidd blood group. Lancet (1981) 1.30
High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant. Am J Transplant (2011) 1.29